Lacipil

Lacidipine, the active ingredient in Lacipil, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by relaxing vascular smooth muscle and lowering blood pressure.

GNH USA supplies Lacipil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacidipine acts on the cardiovascular system to manage elevated blood pressure.

Hypertension: reduces systolic and diastolic pressure, helping to prevent cardiovascular complications.

Lacidipine may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare heart attack events. - Hepatic dysfunction: elevated liver enzymes. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of face, lips, or throat. - Cardiac conduction abnormalities: heart block or arrhythmias.

Before initiating Lacipil, several safety considerations are recommended. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Hepatic function assessment: check liver enzymes periodically. - Concomitant antihypertensives: adjust doses to prevent additive hypotension. - Elderly patients: start at lower doses and monitor closely. - Discontinuation: taper gradually rather than stopping abruptly. - Store at room temperature: keep in the original pack, protect from moisture.

Lacidipine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Lacidipine levels. - Other calcium channel blockers: additive vasodilatory effect. - Grapefruit juice: enhances plasma concentration.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensive agents (e.g., ACE inhibitors, diuretics): monitor for excessive blood pressure reduction.